Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

@article{Demarteau2012CosteffectivenessAO,
  title={Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.},
  author={Nadia Demarteau and Chao Hsiun Tang and Hui-Chi Chen and C. -J. Chen and Georges Van Kriekinge},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2012},
  volume={15 5},
  pages={622-31}
}
OBJECTIVE To compare the epidemiological and economic impact of additional cross-protection against oncogenic human papillomavirus (HPV) types beyond 16/18 of the bivalent vaccine (BV) versus protection against nononcogenic HPV types 6/11 of the quadrivalent vaccine (QV) in Taiwan. METHODS A lifetime Markov model calibrated to the Taiwanese setting simulated the natural history of low-risk (engendering cervical intraepithelial neoplasia [CIN] 1 and genital warts) and high-risk HPV… CONTINUE READING
8 Citations
66 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 66 references

HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. (Abstract O-18.04 presented at the 27th International Papillomavirus

  • P Naud, CM Roteli-Martins, N De Carvalho
  • Conference and Clinical Workshop,
  • 2011

A cost-utility analysis

  • AM Anonychuk, CT Bauch, M Fikre Merid
  • Taiwan. BMC Health Serv Res
  • 2010

A costutility analysis of cervical cancer vaccination in preadolescent Canadian females

  • AM Anonychuk, CT Bauch, M FikreMerid
  • BMC Health Serv Res
  • 2010

Similar Papers

Loading similar papers…